Skip Navigation

European Heart Journal 2000 21(12):967-974; doi:10.1053/euhj.1999.1914
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thambyrajah, J
Right arrow Articles by Townend, J.N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thambyrajah, J
Right arrow Articles by Townend, J.N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Homocysteine and atherothrombosis—mechanisms for injury

J Thambyrajahf1 and J.N Townend

Division of Medical Sciences (Cardiology), University of Birmingham, U.K.

revised August 9, 1999; accepted August 18, 1999

Key Words: Homocysteine, endothelial function and atherosclerosis

f1 Correspondence: Dr J. Thambyrajah, Department of Cardiovascular Medicine, Division of Medical Sciences, University of Birmingham, B15 2TH, U.K.

References

  1. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem. 1992;200:218–229[CrossRef][Web of Science][Medline]
  2. Mansoor MA, Guttormsen AB, Fiskerstrand T, Refsum H, Ueland PM, Svardal AM. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration. Clin Chem. 1993;39:980–985[Abstract/Free Full Text]
  3. McKully KS. Vascular pathology of homocysteinaemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111–128[Web of Science][Medline]
  4. Mudd SH, Levy HZ, Skouby F. Disorders of Transsulphuration. Scriver CR, Beauchet A, Sly WS, Valle D. The Metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1279–1327
  5. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473–501[Web of Science][Medline]
  6. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389[CrossRef][Web of Science][Medline]
  7. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976;57:1079–1082[Web of Science][Medline]
  8. Clarke R, Daly L, Robinson K. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155[Abstract]
  9. Selhub J, Jacques PF, Bostom AG. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286–291[Abstract/Free Full Text]
  10. Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781[Abstract/Free Full Text]
  11. Stampfer MJ, Malinow MR, Willett WC. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–881[Abstract/Free Full Text]
  12. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–709[Abstract/Free Full Text]
  13. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236[Abstract/Free Full Text]
  14. Folsom AR, Nieto FJ, McGovern PG. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204–210[Abstract/Free Full Text]
  15. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 1998;140:349–356[CrossRef][Web of Science][Medline]
  16. Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986;314:488–500[Web of Science][Medline]
  17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809[CrossRef][Medline]
  18. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996;7:389–397[Web of Science][Medline]
  19. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980;18:113–121[CrossRef][Web of Science][Medline]
  20. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol. 1993;108:920–926[Web of Science][Medline]
  21. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5–7[Web of Science][Medline]
  22. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis. 1996;122:163–172[CrossRef][Web of Science][Medline]
  23. Kirkland JB. Lipid peroxidation, protein thiol oxidation and DNA damage in hydrogen peroxide-induced injury to endothelial cells: role of activation of poly(ADP-ribose)polymerase. Biochim Biophys Acta. 1991;1092:319–325[Medline]
  24. Tsai JC, Perrella MA, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369–6373[Abstract/Free Full Text]
  25. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370–1376[Web of Science][Medline]
  26. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following the application of high doses of methionine. Atherosclerosis. 1996;122:201–216[CrossRef][Web of Science][Medline]
  27. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731–741[Web of Science][Medline]
  28. Murad F, Arnold WP, Mittal CK, Braughler JM. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Advances in Cyclic Nucleotide Research. 1979;11:175–204[Medline]
  29. Upchurch GR Jr., Welch GN, Loscalzo J. Homocysteine, EDRF, and endothelial function. J Nutr. 1996;126:1290S–1294S[Abstract/Free Full Text]
  30. Luscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol. 1996;7:234–240[Web of Science][Medline]
  31. Upchurch GR Jr., Welch GN, Fabian AJ, Pigazzi A, Keaney JF Jr., Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis. 1997;132:177–185[CrossRef][Web of Science][Medline]
  32. Ignarro LJ, Gruetter CA. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochim Biophys Acta. 1980;631:221–231[Medline]
  33. Stamler JS, Osborne JA, Jaraki O. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308–318[Web of Science][Medline]
  34. Jia L, Furchgott RF. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1993;267:371–378[Abstract/Free Full Text]
  35. Upchurch GR Jr., Welch GN, Fabian AJ. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012–17017[Abstract/Free Full Text]
  36. Bode-Boger SM, Boger RH, Creutzig A. L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clinical Science. 1994;87:303–310[Web of Science][Medline]
  37. Nappo F, De Rosa N, Marfella R. Impairment of endothelial functions by acute hyperhomocysteinaemia and reversal by antioxidant vitamins. JAMA. 1999;281:2113–2118[Abstract/Free Full Text]
  38. Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol. 1996;270:H1435–1440[Web of Science][Medline]
  39. Joannides R, Haefeli WE, Linder L. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–1319[Abstract/Free Full Text]
  40. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119–1121[Abstract/Free Full Text]
  41. Woo KS, Chook P, Lolin YI. Hyperhomocyst(e)inemia is a risk factor for endothelial dysfunction in humans. Circulation. 1997;96:2542–2544[Abstract/Free Full Text]
  42. Celermajer DS, Sorensen K, Ryalls M. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993;22:854–858[Abstract]
  43. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 1998;351:36–37[Web of Science][Medline]
  44. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998;98:1848–1852[Abstract/Free Full Text]
  45. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156–1160[Abstract/Free Full Text]
  46. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci. 1999;96:235–239[CrossRef][Web of Science][Medline]
  47. Kaufman S. Some metabolic relatioships between biopterin and folate: implications for the ‘methyl trap hypothesis’. Neurochem Res. 1991;16:1031–1036[CrossRef][Web of Science][Medline]
  48. Verhaar MC, Wever RM, Kastelein JJ, van DT, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998;97:237–241[Abstract/Free Full Text]
  49. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996;97:979–987[Web of Science][Medline]
  50. Ziegler DM. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu Rev Biochem. 1985;54:305–329[Web of Science][Medline]
  51. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA. 1981;78:2249–2252[Abstract/Free Full Text]
  52. Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. FASEB J. 1988;2:116–123[Abstract]
  53. Hajjar K. Assembly of the fibrinolytic system on endothelial cells. Haber E, Braunwald E. Thrombolysis: Basic Contributions and Clinical Progress. : Mosby-Year Book; 1991. p. 27–32
  54. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993;91:2873–2879[Web of Science][Medline]
  55. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909–1916[Web of Science][Medline]
  56. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler & Thrombosis. 1993;13:1327–1333[Abstract/Free Full Text]
  57. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:1381–1386[Web of Science][Medline]
  58. Palareti G, Salardi S, Piazzi S. Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific therapy. J Pediatr. 1986;109:1001–1006[CrossRef][Web of Science][Medline]
  59. Giannini MJ, Coleman M, Innerfield I. Letter: Antithrombin activity in homocystinuria. Lancet. 1975;1:1094[Web of Science][Medline]
  60. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895–901[Abstract/Free Full Text]
  61. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1906–1914[Web of Science][Medline]
  62. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992;79:2930–2936[Abstract/Free Full Text]
  63. Lentz SR, Sobey CG, Piegors DJ. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24–29[Web of Science][Medline]
  64. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA. 1992;89:10193–10197[Abstract/Free Full Text]
  65. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S–1289S[Abstract/Free Full Text]
  66. Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prostaglandins Leukotriences & Medicine. 1986;22:349–356
  67. Wang J, Dudman NP, Wilcken DE. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost. 1993;70:1047–1052[Web of Science][Medline]
  68. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res. 1982;16:490–493[Web of Science][Medline]
  69. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537–543[Web of Science][Medline]
  70. Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med. 1976;295:1283–1286[Abstract]
  71. Hill-Zobel RL, Pyeritz RE, Scheffel U. Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria. N Engl J Med. 1982;307:781–786[Abstract]
  72. McDonald L, Bray C, Field C, Love F, Davies B. Homocystinuria, thrombosis and the blood platelets. Lancet. 1964;i:745–746[CrossRef]
  73. Di Minno G, Davi G, Margaglione M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400–1406[Web of Science][Medline]
  74. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol. 1998;274:C396–405[Medline]
  75. Tsai JC, Wang H, Perrella MA. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146–153[Web of Science][Medline]
  76. Hunter T, Pines J. Cyclins and cancer. Cell. 1991;66:1071–1074[CrossRef][Web of Science][Medline]
  77. Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059–1065[Web of Science][Medline]
  78. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991;67:1169–1179[CrossRef][Web of Science][Medline]
  79. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551–555[CrossRef][Web of Science][Medline]
  80. Lubec B, Labudova O, Hoeger H. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation. 1996;94:2620–2625[Abstract/Free Full Text]
  81. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 1987;917:337–340[Medline]
  82. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 1993;34:2051–2061[Abstract]
  83. Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis. 1994;105:165–170[CrossRef][Web of Science][Medline]
  84. Blom HJ, Kleinveld HA, Boers GH. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest. 1995;25:149–154[Web of Science][Medline]
  85. Halvorsen B, Brude I, Drevon CA. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res. 1996;37:1591–1600[Abstract]
  86. Blom HJ, Engelen DP, Boers GH. Lipid peroxidation in homocysteinaemia. J Inherit Metab Dis. 1992;15:419–422[CrossRef][Web of Science][Medline]
  87. Dudman NP, Wilcken DE, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia. Relevance to development of arteriosclerosis. Arteriosclerosis & Thrombosis. 1993;13:512–516[Abstract/Free Full Text]
  88. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res. 1999;84:409–416[Abstract/Free Full Text]
  89. Poddar R, Sivasubramaniam N, Robinson K, Jacobsen DW. Homocysteine modulates the expression of a specific cytokine (Monocyte chemoattractant protein-1) in human aortic endothelial cells. Circulation. 1997;96:I-286
  90. Dudman NPB, Hale SET. Endothelial and leukocyte-mediated mechanisms in homocysteine-associated occlusive vascular disease. Graham I, Refsum H, Rosenberg IH, Ueland PM. Homocysteine metabolism: From basic science to clinical medicine. Boston: Kluwer Academic; 1997. p. 267–271
  91. van der Molen EF, van den Heuvel LP, te Poele Pothoff MT, Monnens IA, Eskes TK, Blom HJ. The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs). Eur J Clin Invest. 1996;26:304–309[CrossRef][Web of Science][Medline]
  92. Saez G, Thornalley PJ, Hill HA, Hems R, Bannister JV. The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta. 1982;719:24–31[Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
A. de Bree, L. A van Mierlo, and R. Draijer
Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 610 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Zinellu, E. Zinellu, S. Sotgia, M. Formato, G. M. Cherchi, L. Deiana, and C. Carru
Factors Affecting S-Homocysteinylation of LDL Apoprotein B
Clin. Chem., November 1, 2006; 52(11): 2054 - 2059.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Vignini, L. Nanetti, T. Bacchetti, G. Ferretti, G. Curatola, and L. Mazzanti
Modification Induced by Homocysteine and Low-Density Lipoprotein on Human Aortic Endothelial Cells: An In Vitro Study
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4558 - 4561.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
G. Vrentzos, J. A. Papadakis, N. Malliaraki, E. A. Zacharis, K. Katsogridakis, A. N. Margioris, P. E. Vardas, and E. S. Ganotakis
Association of Serum Total Homocysteine with the Extent of Ischemic Heart Disease in a Mediterranean Cohort
Angiology, September 1, 2004; 55(5): 517 - 524.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
W. Koch, G. Ndrepepa, J. Mehilli, S. Braun, M. Burghartz, H. Lengnick, K. Kolling, A. Schomig, and A. Kastrati
Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries
Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2229 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom
Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease
Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
A. De Bree, W. M. Verschuren, D. Kromhout, L. I Mennen, H. J Blom, E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, et al.
Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects
Int. J. Epidemiol., December 1, 2002; 31(6): 1268 - 1272.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Nurk, G. S. Tell, S. E. Vollset, O. Nygard, H. Refsum, and P. M. Ueland
Plasma Total Homocysteine and Hospitalizations for Cardiovascular Disease: The Hordaland Homocysteine Study
Arch Intern Med, June 24, 2002; 162(12): 1374 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Thambyrajah, M. J. Landray, H. J. Jones, F. J. McGlynn, D. C. Wheeler, and J. N. Townend
A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1858 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Thambyrajah, M. J. Landray, F. J. McGlynn, H. J. Jones, D. C. Wheeler, and J. N. Townend
Does Folic Acid Decrease Plasma Homocysteine and Improve Endothelial Function in Patients With Predialysis Renal Failure?
Circulation, August 22, 2000; 102(8): 871 - 875.
[Abstract] [Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thambyrajah, J
Right arrow Articles by Townend, J.N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thambyrajah, J
Right arrow Articles by Townend, J.N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?